Anal Cancer - Pipeline Review, H1 2015

Description: Anal Cancer - Pipeline Review, H1 2015

Summary


This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Anal Cancer Overview
Therapeutics Development
Pipeline Products for Anal Cancer - Overview
Pipeline Products for Anal Cancer - Comparative Analysis
Anal Cancer - Therapeutics under Development by Companies
Anal Cancer - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Anal Cancer - Products under Development by Companies
Anal Cancer - Companies Involved in Therapeutics Development
Advaxis, Inc.
Amgen Inc.
Eli Lilly and Company
ISA Pharmaceuticals B.V.
MedImmune, LLC
Theravectys S.A.
Anal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADXS-HPV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
durvalumab + tremelimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISA-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-2606368 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panitumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for HPV Associated Cancers - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anal Cancer - Recent Pipeline Updates
Anal Cancer - Dormant Projects
Anal Cancer - Product Development Milestones
Featured News & Press Releases
Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product
Candidate in Anal Cancer
Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience
Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV
Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV
Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy
Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Anal Cancer, H1 2015
Number of Products under Development for Anal Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Anal Cancer - Pipeline by Advaxis, Inc., H1 2015
Anal Cancer - Pipeline by Amgen Inc., H1 2015
Anal Cancer - Pipeline by Eli Lilly and Company, H1 2015
Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2015
Anal Cancer - Pipeline by MedImmune, LLC, H1 2015
Anal Cancer - Pipeline by Theravectys S.A., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

List of Figures
Number of Products under Development for Anal Cancer, H1 2015
Number of Products under Development for Anal Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3112080/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Anal Cancer - Pipeline Review, H1 2015
Web Address: http://www.researchandmarkets.com/reports/3112080/
Office Code: SCD2STUI

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 6000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp